Solid Biosciences (SLDB) to Release Quarterly Earnings on Tuesday

Key Points

• Solid Biosciences is set to release its Q2 2025 earnings before the market opens on August 12th, with analysts projecting a loss of ($0.51) per share for the quarter.
• Previously, the company reported a loss of ($0.59) per share for the last quarter, missing estimates by ($0.06).
• A significant portion of Solid Biosciences' stock, approximately 81.46%, is owned by institutional investors, indicating strong institutional confidence in the company's potential.

Solid Biosciences (NASDAQ:SLDB - Get Free Report) is projected to release its Q2 2025 earnings data before the market opens on Tuesday, August 12th. Analysts expect the company to announce earnings of ($0.51) per share for the quarter.

Solid Biosciences (NASDAQ:SLDB - Get Free Report) last issued its earnings results on Thursday, May 15th. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.06). On average, analysts expect Solid Biosciences to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Solid Biosciences Trading Down 4.5%

NASDAQ SLDB traded down $0.30 during trading on Thursday, reaching $6.21. 507,061 shares of the company's stock were exchanged, compared to its average volume of 1,966,196. The firm has a market capitalization of $481.68 million, a PE ratio of -2.08 and a beta of 2.44. Solid Biosciences has a fifty-two week low of $2.41 and a fifty-two week high of $10.37. The company's fifty day simple moving average is $5.28 and its 200-day simple moving average is $4.28.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Cantor Fitzgerald set a $16.00 price target on Solid Biosciences and gave the company an "overweight" rating in a research note on Monday, July 21st. Piper Sandler reduced their price target on shares of Solid Biosciences from $20.00 to $17.00 and set an "overweight" rating for the company in a report on Friday, May 16th. Chardan Capital lowered their price objective on Solid Biosciences from $16.00 to $15.00 and set a "buy" rating on the stock in a research report on Monday, May 19th. HC Wainwright reiterated a "buy" rating and set a $20.00 price target on shares of Solid Biosciences in a research note on Tuesday, June 17th. Finally, Wedbush dropped their price target on shares of Solid Biosciences from $18.00 to $17.00 and set an "outperform" rating for the company in a research report on Friday, May 16th. Ten equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $15.10.

Institutional Investors Weigh In On Solid Biosciences

Institutional investors have recently modified their holdings of the business. Woodline Partners LP purchased a new stake in Solid Biosciences during the 1st quarter valued at approximately $2,338,000. Goldman Sachs Group Inc. lifted its stake in Solid Biosciences by 32.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 180,137 shares of the company's stock worth $667,000 after purchasing an additional 43,910 shares in the last quarter. Finally, AQR Capital Management LLC purchased a new position in shares of Solid Biosciences during the first quarter valued at about $418,000. 81.46% of the stock is owned by hedge funds and other institutional investors.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.